Phase 3 Readout~month

Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to

Name: Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to
Start: 2028-04-01

April 1, 2028

Company: MEDICINOVA INC (MNOV)
Drug: amyotrophic
Indication: Amyotrophic Lateral Sclerosis

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to — MNOV Phase 3 Readout | BioSniper